Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology (ASCO) Annual Meeting
First Presentation of Data from EV-201 Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Featured in an Oral Session on Monday, June 3 rd BOTHELL, Wash. --(BUSINESS WIRE)--May 15, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from six of its
View HTML
Toggle Summary Seattle Genetics to Present at RBC Capital Markets 2019 Global Healthcare Conference
BOTHELL, Wash. --(BUSINESS WIRE)--May 15, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the RBC Capital Markets 2019 Global Healthcare Conference on Wednesday, May 22, 2019 at 8:30 a.m. Eastern Time . The presentation will be webcast live and available
View HTML
Toggle Summary Seattle Genetics Announces Progress in Expanding ADCETRIS® (Brentuximab Vedotin) Indications in Canada
-Health Canada Approves ADCETRIS in Combination with AVD Chemotherapy for the Treatment of Previously Untreated Hodgkin Lymphoma Based on Positive Phase 3 ECHELON-1 Clinical Trial Results- -Supplemental New Drug Submission Completed for ADCETRIS in Combination with CHP Chemotherapy in Frontline
View HTML
Toggle Summary Seattle Genetics Reports First Quarter 2019 Financial Results
-ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada Were $135.0 Million in the First Quarter, an Increase of 42 Percent Over the First Quarter of 2018- -Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Support Planned
View HTML
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2019 Financial Results on April 25, 2019
BOTHELL, Wash. --(BUSINESS WIRE)--Apr. 4, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets. Following the announcement, company management will host a conference
View HTML
Toggle Summary Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
-Phase 2 innovaTV 204 Trial Designed to Support Potential Accelerated Approval Pathway in U.S.- BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 29, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced completion of enrollment in the potentially pivotal innovaTV 204 phase 2 clinical trial evaluating
View HTML
Toggle Summary Seattle Genetics to Host Conference Call on Positive Topline Results from Pivotal Trial of Enfortumab Vedotin
BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 28, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) will host a conference call and webcast discussion regarding the positive topline results from its pivotal clinical trial of enfortumab vedotin in locally advanced or metastatic urothelial cancer, which were
View HTML
Toggle Summary Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
- Companies Plan to Submit Biologics License Application Later This Year - - Seattle Genetics to Hold Conference Call Today at 9:00 a.m. EDT - BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Mar. 28, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc.
View HTML
Toggle Summary Seattle Genetics Highlights Antibody-Drug Conjugate Innovation and Immuno-Oncology Program at the American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 27, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data highlights from six presentations showcasing technology advances in the company’s antibody-drug conjugate (ADC) platform and an immuno-oncology program at the American Association for Cancer
View HTML
Toggle Summary Seattle Genetics to Present at Cowen and Company 39th Annual Health Care Conference
BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 5, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, March 12, 2019 at 10:40 a.m. Eastern Time . The presentation will be webcast live and available
View HTML